Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
Portfolio Pulse from
Neurocrine Biosciences reported strong financial results for 2024, with significant growth in sales of INGREZZA and the launch of CRENESSITY. The company provided optimistic sales guidance for 2025 and announced new phase 3 programs.
February 06, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences reported a 26% increase in INGREZZA sales for 2024 and launched CRENESSITY in the US. The company expects 2025 sales to reach $2.5-$2.6 billion and is initiating new phase 3 programs.
The strong sales growth of INGREZZA and the launch of CRENESSITY indicate robust product performance and market expansion. The positive sales guidance for 2025 and new phase 3 programs suggest continued growth potential, likely boosting investor confidence and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100